Presentation is loading. Please wait.

Presentation is loading. Please wait.

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

Published byChristal Caldwell Modified over 5 years ago

Similar presentations

Presentation on theme: "A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children."— Presentation transcript:

1 A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis  M.W. Konstan, G. Döring, S.L. Heltshe, L.C. Lands, K.A. Hilliard, P. Koker, S. Bhattacharya, A. Staab, A. Hamilton  Journal of Cystic Fibrosis  Volume 13, Issue 2, Pages (March 2014) DOI: /j.jcf Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

2 Fig. 1 Subject disposition, consort diagram.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

3 Fig. 2 Time to protocol-defined pulmonary exacerbation.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

4 Fig. 3 Change in lung function.
Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Download ppt "A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children."

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis  Nataliya Y. Kashirskaya, Nikolay I. Kapranov,

Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis  Nataliya Y. Kashirskaya, Nikolay I. Kapranov,
Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.

Efficacy and safety of Creon�� 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis  Bruce C. Trapnell, Karen Maguiness, Gavin.
Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations 

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations 
Treatment compliance in children and adults with Cystic Fibrosis

Treatment compliance in children and adults with Cystic Fibrosis
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H
Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled.
Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D

Patrick A. Flume, John P. Clancy, George Z. Retsch-Bogart, D
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.

Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,
Cirrhosis and other liver disease in cystic fibrosis

Cirrhosis and other liver disease in cystic fibrosis
John Widger, Sarath Ranganathan, Philip J. Robinson 

John Widger, Sarath Ranganathan, Philip J. Robinson 
Pulmonary exacerbations in CF patients with early lung disease

Pulmonary exacerbations in CF patients with early lung disease
Controlled clinical trials in cystic fibrosis — are we doing better?

Controlled clinical trials in cystic fibrosis — are we doing better?
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.

Similar presentations

Ads by Google